A phase II study of Chinese patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) for metastatic pancreatic cancer (MPC)

被引：0
|
作者：
Shen, Lin
Yu, Xianjun
Hao, Jihui
Wang, Liwei
Pan, Hongming
Han, Guohong
Xu, Jian-Ming
Zhang, Yanqiao
Yang, Shujun
Chen, Jia
Ying, Jieer
Dai, Guanghai
Li, Mingyu
Begic, Damir
Lu, Brian D.
Xu, Ruihua
机构：
[1] Beijing Canc Hosp, Beijing, Peoples R China
[2] Fudan Univ, Shanghai Canc Ctr, Shanghai 200433, Peoples R China
[3] Tianjin Canc Hosp, Tianjin, Peoples R China
[4] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Shanghai 200030, Peoples R China
[5] Sir Run Run Shaw Hosp, Hangzhou, Zhejiang, Peoples R China
[6] Fourth Mil Med Univ, Dept Liver Dis & Digest Intervent Radiol, Xijing Hosp Digest Dis, Xian 710032, Peoples R China
[7] Acad Mil Med Sci, Hosp 307, Ctr Canc, Beijing, Peoples R China
[8] Harbin Med Univ, Affiliated Hosp 3, Harbin, Peoples R China
[9] Henan Canc Hosp, Zhengzhou, Peoples R China
[10] Jiangsu Canc Hosp, Nanjing, Jiangsu, Peoples R China
[11] Zhejiang Canc Hosp, Dept Chemotherapy, Hangzhou, Zhejiang, Peoples R China
[12] Peoples Liberat Army, Gen Hosp, Beijing, Peoples R China
[13] Celgene Corp, Summit, NJ USA
[14] Celgene Corp, Madison, NJ USA
[15] Sun Yat Sen Univ, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.327
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
327
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Tumor burden reduction between primary and metastatic sites in advanced pancreatic cancer patients (pts) undergoing chemotherapy with nab-paclitaxel (Nab-P) and gemcitabine (Gem)
    Ventriglia, J.
    Laterza, M. M.
    Savastano, B.
    Petrillo, A.
    Tirino, G.
    Diana, A.
    Troiani, T.
    Ciardiello, F.
    De Vita, F.
    ANNALS OF ONCOLOGY, 2015, 26 : 101 - 102
  • [22] Phase IB trial of ADI-PEG 20 (A) plus nab-paclitaxel (nab-P) and gemcitabine (gem) in patients with advanced pancreatic cancer (PC)
    Lowery, Maeve Aine
    Harding, James J.
    Yu, Kenneth H.
    Kelsen, David Paul
    Bomalaski, John S.
    Glassman, Danielle C.
    Covington, Christina M.
    Brenner, Robin
    Hollywood, Ellen
    Barba, Adalberto
    Johnston, Amanda
    Liu, Kay Chia-Wei
    Capanu, Marinela
    Abou-Alfa, Ghassan K.
    O'Reilly, Eileen Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [23] APACT: A Phase III Trial of Nab-Paclitaxel (nab-P) Plus Gemcitabine (Gem) Versus Gem Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (PC)
    Tempero, Margaret
    Cardin, Dana
    Biankin, Andrew
    Goldstein, David
    Moore, Malcolm
    O'Reilly, Eileen
    Philip, Philip
    Riess, Hanno
    Macarulla, Teresa
    Yung, Lotus
    Wei, Xinyu
    Lu, Brian
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S72 - S72
  • [24] A phase II study of nab-paclitaxel and gemcitabine in Korean patients with metastatic pancreatic cancer
    Lee, S. J.
    Oh, D-Y.
    Kang, J-H.
    Choi, H. J.
    Lee, M. A.
    Oh, S. Y.
    Kim, S-T.
    Park, Y. S.
    Ryu, B-Y.
    Park, J. O.
    ANNALS OF ONCOLOGY, 2018, 29
  • [25] nab-paclitaxel (nab-P) plus gemcitabine (Gem) vs Gem alone as adjuvant treatment for resected pancreatic cancer (PC) in a phase III trial (APACT).
    Tempero, Margaret A.
    Cardin, Dana Backlund
    Biankin, Andrew
    Goldstein, David
    Moore, Malcolm
    O'Reilly, Eileen Mary
    Philip, Philip Agop
    Riess, Hanno
    Macarulla, Teresa
    Yung, Lotus
    Li, Mingyu
    Lu, Brian
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [26] Gemcitabine (G) and nab-paclitaxel (nab-P) in patients with refractory advanced pancreatic cancer (PC).
    Ernani, Vinicius
    Akunyili, Ikechukwu Immanuel
    Hosein, Peter Joel
    Macintyre, Jessica
    Lima, Caio Max S. Rocha
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [27] Reduction in primary pancreatic and metastatic tumor burden in the phase III MPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone.
    Kunzmann, Volker
    Ramanathan, Ramesh K.
    Goldstein, David
    Penenberg, Darryl Neil
    Ferrara, Stefano
    Lu, Brian D.
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [28] Phase Ib study of WNT inhibitor ipafricept (IPA) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (mPC).
    Dotan, Efrat
    Cardin, Dana Backlund
    Lenz, Heinz-Josef
    Messersmith, Wells A.
    O'Neil, Bert
    Cohen, Steven J.
    Denlinger, Crystal S.
    Shahda, Safi
    Kapoun, Ann M.
    Brachmann, Rainer Karl
    Uttamsingh, Shailaja
    Weekes, Colin D.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [29] FOLFOX and nab-paclitaxel (nab-P) for advanced pancreatic cancer: A phase I study
    Safran, Howard
    Charpentier, Kevin
    Perez, Kimberly
    Mantripragada, Kalyan
    Austin, Trevor Clark
    Nadeem, Omar
    Lombardo, Alise
    Houlihan, Lindsay
    Fontes-Borts, Lucia
    Kolberg, Irene
    Mitchell, Kristen
    Rosati, Kayla
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [30] Prognostic factors (PFs) of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with metastatic pancreatic cancer (MPC).
    Moore, Malcolm J.
    Von Hoff, Daniel D.
    Ervin, Thomas J.
    Arena, Francis P.
    Chiorean, E. Gabriela
    Infante, Jeffrey R.
    Hon, Jeremy K.
    Biakhov, Mikhail Yu
    Hingorani, Sunil R.
    Ganju, Vinod
    Weekes, Colin D.
    Scheithauer, Werner
    Ramanathan, Ramesh K.
    Tabernero, Josep
    Goldstein, David
    Wei, Xinyu
    Romano, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345